Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This study combines vyxeos and gilteritinib in patients with relapsed or refractory
FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given as induction
therapy. Those patients entering a complete remission or a complete remission with incomplete
blood count recovery will be allowed to proceed to consolidation therapy with vyxeos and
gilteritinib. Those patients who do not proceed to an allogeneic stem cell transplant for any
reason are able to enter the maintenance phase of this trial using daily gilteritinib
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute